For over 25 years, Anne has been advising major pharmaceutical and biotech companies on competition law and regulatory matters related to pharmaceuticals, biologicals, medical devices, food supplements, CBD products and cosmetics.
Anne advises clients at each step of their product’s life, from R&D to withdrawals. She assists originator companies, especially for advanced therapy medicines, in all aspects of their market access strategy: early access, compassionate use, transition to MA, final payback, reimbursement strategy, pricing negotiations.
She also handles all regulatory matters: advertising, communication on social media, transparency, patient support programs.
Her extensive expertise in competition matters includes the development and management of supply chain management schemes, life-cycle management.
In parallel, Anne has been highly engaged in the field of medical cannabis since the launch of the pilot program in France. She supported stakeholders and project leaders in their interactions with the relevant public authorities.
She contributed to the drafting and evolution of the various draft texts that enabled the creation and integration into general legal framework of a specific status for cannabis-based medicines, as well as the definition of product specifications, cultivation conditions, and manufacturing, distribution, and export procedures for pharmaceutical raw materials and finished products.
